ST Pharm Co.,Ltd. (KOSDAQ: 237690)

Market Cap	1.73T
Revenue (ttm)	278.64B
Net Income (ttm)	32.39B
Shares Out	20.15M
EPS (ttm)	1,689.86
PE Ratio	50.77
Forward PE	34.96
Dividend	500.00 (0.59%)
Ex-Dividend Date	Dec 27, 2024

Volume	197,015
Average Volume	159,433
Open	86,200
Previous Close	85,800
Day's Range	86,100 - 90,400
52-Week Range	60,000 - 120,800
Beta	0.59
RSI	45.12
Earnings Date	Jan 31, 2025

About ST Pharm Co.,Ltd.

ST Pharm Co.,Ltd., provides custom manufacturing services for active pharmaceutical ingredient and intermediates in South Korea and internationally. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical R and D solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co....

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2023, ST Pharm Co.,Ltd.'s revenue was 284.99 billion, an increase of 14.31% compared to the previous year's 249.32 billion. Earnings were 19.58 billion, an increase of 8.78%.